Company Profiles

driven by the PitchBook Platform

Aerpio Therapeutics

Aerpio Therapeutics
2011 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
PIPE LATEST DEAL TYPE
$40M LATEST DEAL AMOUNT
$111M TOTAL AMOUNT RAISED
Description

Developer of novel therapies designed to treat vascular disorders. The company develops diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease providing the treatment for diabetic eye disease without repeated injections into the eye.

Website:
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
9987 Carver Road
Suite 420
Cincinnati, OH 45242
United States
+1 (513) 985-1920
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aerpio Therapeutics’s full profile, request a free trial.

Aerpio Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. PIPE 16-Mar-2017 $40M $111M Completed Clinical Trials - General
5. Reverse Merger 15-Mar-2017 0000 Completed Clinical Trials - General
4. Convertible Debt 10-Nov-2016 00.000 0000 Completed Clinical Trials - General
3. Early Stage VC (Series A2) 23-Apr-2014 0000 0000 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A1) 06-Nov-2013 $36M $41M $42.3M Completed Startup
1. Early Stage VC (Series A) 05-Jan-2012 $5M $5M $6.13M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Aerpio Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A1 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 3,094,774 $0.000010 6% $1.83 $1.83 1x $1.83 7.74%
To view this company’s complete Cap Table request access »

Aerpio Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Ally Bridge Group Venture Capital Minority 000 0000 000000 0
AmorChem Venture Capital Minority 000 0000 000000 0
Athenian Venture Partners Venture Capital Minority 000 0000 000000 0
CincyTech Venture Capital Minority 000 0000 000000 0
Kearny Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Aerpio Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Joseph Gardner Ph.D Chief Executive Officer, President & Board Member
Kevin Peters Chief Scientific Officer
Sally Graves Controller
Mitchell Brigell Ph.D Vice President of Clinical Development and VP and Director of Clinical Sciences, Ophthalmology
Dhaval Desai Vice President, Medical Affairs
You’re viewing 5 of 6 executives. Get the full list »

Aerpio Therapeutics Board Members (15)

Name Representing Role Since Contact
Info
Adrienne Graves Ph.D Self Board of Directors 000 0000
Anupam Dalal MD Kearny Venture Partners Board Member 000 0000
Caley Castelein MD Kearny Venture Partners Board Member 000 0000
Campbell Murray MD Novartis Venture Fund Board Member 000 0000
Chau Khuong OrbiMed Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »